Google Übersetzer
Amylyx Pharmaceuticals Inc
About
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 8 2026
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Mar 24 2026
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Mar 3 2026
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 24 2026
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Jan 8 2026
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
Recent Videos
Amylyx ($AMLX): Zero Revenue, Infinite Potential? The Full Drill Down
Mar 07, 2026
Amylyx Pharmaceuticals Inc. 2025 annual report
Mar 04, 2026
Amylyx Pharmaceuticals (AMLX|$1.7B) - 2025 Q4 & Full Year Earnings Analysis
Mar 04, 2026
Amylyx Pharmaceuticals Q4 2025 Earnings Call
Mar 04, 2026
Financials
Revenue
-$665 K
Market Cap
$1.65 B
EPS
-1.53